AMGN Add to watchlist $348.22 2.73 (-0.78%) Last updated: Apr 16, 2026 00:43
52-Week Range
$348.22
$261.43 $348.22 $391.29

Fundamentals Overview

Amgen Inc. is in the middle of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/E 24.5 PEG 0.28 P/B 21.68 P/S 5.11

Intrinsic value (DCF)

+210.8% upside vs price

Profitability

Net margin 21%

Risk (Beta)

0.47 — lower vol

Earnings & growth

EPS $14.20 Rev +3.5% Profit -58.6% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 73% confidence Risk: Lower Volatility — Beta 0.47. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +210.8% upside vs price · Analyst grade: B+ · 3M vs S&P 500: +6.3% · 3M vs Healthcare sector: +13.1%

Pressures (Sell):

Sentiment weakening (2 downgrades)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$187.71B
P/E (TTM)
24.52
EPS (TTM)
$14.20
Dividend Yield
2.77%
52-Week Range
$261.43 - $391.29
Volume vs Avg
N/A
Beta
0.47

About

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-rel...
Sector: Healthcare
Headquarters: US
Employees: 28,000
IPO Date: Jun 1983
Website: www.amgen.com
Beta: 0.47 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 3, Equal Weight: 7, Hold: 3, Market Perform: 1, Neutral: 8, Outperform: 3, Overweight: 4, Underperform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $1,082.39; current price is $348.22. That’s a +210.8% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 24.52
DCF value (model) $1,082.39 (210.8% upside)
PEG (TTM) 0.28
P/B (TTM) 21.68
P/S (TTM) 5.11
P/FCF (TTM) 23.17
Liquidity & enterprise
Current Ratio (TTM) 1.14
Quick Ratio (TTM) 0.9
Cash Ratio (TTM) 0.36
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 20.97%
Gross margin (TTM) 70.49%
Operating margin (TTM) 27.99%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for AMGN.

Analyst Sentiment at a Glance

B+ Sentiment Weakening
Buy 3Equal Weight 7Hold 3Market Perform 1Neutral 8Outperform 3Overweight 4Underperform 1
0 upgrades, 2 downgrades
Price Target Consensus
Current $348.22
Median $353.00
Consensus $349.44
Low consensus $185.00
High consensus $432.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
UBS maintain Buy Buy 2026-04-13
Morgan Stanley maintain Equal Weight Equal Weight 2026-04-10
Guggenheim maintain Neutral Neutral 2026-04-09
Cantor Fitzgerald maintain Neutral Neutral 2026-04-08
Wells Fargo maintain Equal Weight Equal Weight 2026-02-19
Piper Sandler maintain Overweight Overweight 2026-02-18
Freedom Broker downgrade Buy Hold 2026-02-12
Guggenheim maintain Neutral Neutral 2026-02-06
Argus Research maintain Buy Buy 2026-02-06
Leerink Partners maintain Outperform Outperform 2026-02-04
Citigroup maintain Neutral Neutral 2026-02-04
Morgan Stanley maintain Equal Weight Equal Weight 2026-02-04
Cantor Fitzgerald maintain Neutral Neutral 2026-02-04
UBS maintain Buy Buy 2026-01-26
Bernstein downgrade Outperform Market Perform 2026-01-20
Truist Securities maintain Hold Hold 2026-01-08
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-12
Wells Fargo maintain Equal Weight Equal Weight 2025-12-10
BMO Capital maintain Outperform Outperform 2025-12-03
Leerink Partners maintain Outperform Outperform 2025-11-27
Piper Sandler maintain Overweight Overweight 2025-11-14
Freedom Broker maintain Hold Hold 2025-11-12
Cantor Fitzgerald maintain Neutral Neutral 2025-11-06
Wells Fargo maintain Overweight Overweight 2025-11-05
Morgan Stanley maintain Equal Weight Equal Weight 2025-11-05
B of A Securities maintain Underperform Underperform 2025-09-26
Piper Sandler maintain Overweight Overweight 2025-08-25
Morgan Stanley maintain Equal Weight Equal Weight 2025-08-06
UBS maintain Neutral Neutral 2025-08-06
Citigroup maintain Neutral Neutral 2025-08-06